Pure Global AI
NCT06367192Recruiting

School Readiness Intervention for Preschool Children With Sickle Cell Disease

St. Jude Children's Research HospitalClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Sickle Cell Disease
Drug/Device/Intervention
The adapted Kids in Transition to School Intervention
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
St. Jude Children's Research Hospital
Location
Memphis, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Oct 01, 2028
Enrollment
36 participants
Primary outcome

Feasibility of Intervention Measure,Acceptability of Intervention Measure

Summary

The study participant is being asked to take part in this clinical trial, a type of research
 study, because the participant is a young child with sickle cell disease or the caregiver of
 a child with sickle cell disease. This study is being done to test a school readiness program
 for children with sickle cell disease (ages 4-6 years old).
 
 Primary Objective
 
 Assess feasibility and acceptability of an adapted school readiness intervention among
 preschool children (ages 4-6) diagnosed with sickle cell disease.
 
 Secondary Objectives
 
 Objective 1:
 
 Measure preliminary efficacy of the adapted school readiness intervention compared to routine
 care among preschool children ages (4-6) diagnosed with sickle cell disease.
 
 Objective 2:
 
 Examine implementation factors (i.e., barriers and facilitators) during post-intervention.

ICD-10 classifications
Sickle-cell disordersOther sickle-cell disordersSickle-cell traitSickle-cell anaemia with crisisSickle-cell anaemia without crisis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06367192
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06367192 through Pure Global AI's free database. This phase not specified trial is sponsored by St. Jude Children's Research Hospital and is currently Recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.